Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

ANI Pharmaceuticals Inc (ANIP) reports a robust quarter with significant revenue growth and upward revisions in 2025 guidance, driven by strong performance in rare disease and generics segments.

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis ...

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of ...

ANI Pharmaceuticals' Q2 2025 earnings report highlights record revenues, strong Cortrophin Gel demand, and raised guidance.